Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

NCT00523341 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00523341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00523341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
August 7, 2007
Completion date
July 19, 2015
Enrollment
4,550 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteopenia, osteoporosis